Echocardiography has played a critical role in the development of advanced surgical techniques for the management of patients with valvular regurgitation and heart failure. The following pre- and ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's ...

The aorta is the main artery of the human body. Its large structure is key to maintaining the vital function of pumping oxygenated blood around the whole body. Aortic ...

WASHINGTON — A phase 3 randomized trial will soon begin for the first transcatheter aortic valve replacement (TAVR) device for the treatment of aortic valve regurgitation after promising results in a ...

Aortic insufficiency occurs when your aortic valve fails to close properly once the blood enters the aorta. This causes blood to flow the wrong way back into the heart. When the left ventricle doesn’t ...

SAN FRANCISCO -- Aortic valve regurgitation treated with the investigational JenaValve Trilogy appeared safe and effective in the ALIGN AR trial. The device met the safety benchmark, with a 26.7% rate ...

The FDA approved the Trilogy Transcatheter Heart Valve System for the treatment of symptomatic severe aortic regurgitation, device maker JenaValve Technology announced. This approval makes Trilogy the ...

Please provide your email address to receive an email when new articles are posted on . A transcatheter aortic valve replacement system designed to treat aortic regurgitation exceeded its safety and ...